<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00043108</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000256334</org_study_id>
    <secondary_id>P30CA006927</secondary_id>
    <secondary_id>NCI-G02-2097</secondary_id>
    <secondary_id>02-014</secondary_id>
    <nct_id>NCT00043108</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer</brief_title>
  <official_title>Trimodality Protocol for the Treatment of Locally Advanced, Potentially Resectable Non-Small Cell Lung Cancer Targeting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fox Chase Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fox Chase Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.&#xD;
      Giving combination chemotherapy with radiation therapy before and after surgery may shrink&#xD;
      the tumor so it can be removed during surgery and may kill any remaining tumor cells&#xD;
      following surgery.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining paclitaxel and carboplatin&#xD;
      with radiation therapy and surgery in treating patients who have newly diagnosed locally&#xD;
      advanced non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the complete resection rate and toxic death rate of patients with locally&#xD;
           advanced non-small cell lung cancer treated with paclitaxel, carboplatin, and&#xD;
           radiotherapy followed by surgical resection and adjuvant paclitaxel and carboplatin.&#xD;
&#xD;
        -  Determine the survival, event-free survival, and incidence of pathologic complete&#xD;
           remission of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the protocol completion rate (CR) of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the feasibility and toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Determine the pathologic response rate/downstaging, pathologic near CR rate, freedom&#xD;
           from distant metastasis rate, and freedom from local regional failure rate of patients&#xD;
           treated with this regimen.&#xD;
&#xD;
      OUTLINE: Patients receive induction therapy comprising radiotherapy 5 days a week for 5.5-6&#xD;
      weeks and paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on days 1, 8, 15, 22,&#xD;
      29, and 36.&#xD;
&#xD;
      Within 1-3 weeks after completion of induction therapy, patients undergo restaging. Patients&#xD;
      with resectable disease undergo surgical resection within 4-8 weeks after induction therapy.&#xD;
      Patients with unresectable disease undergo additional radiotherapy 5 days a week for 3 weeks&#xD;
      and receive paclitaxel and carboplatin as in induction therapy on days 1, 8, and 15.&#xD;
&#xD;
      Within 4-12 weeks after surgery or additional chemoradiotherapy, patients receive adjuvant&#xD;
      therapy comprising paclitaxel and carboplatin as in induction therapy on day 1. Adjuvant&#xD;
      treatment repeats every 4 weeks for 3 courses.&#xD;
&#xD;
      Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then&#xD;
      annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 57 patients will be accrued for this study within 4 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxic death rate</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete resection rates</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic complete remission (pCR)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thoracic RT (50.4 Gy/1.8 Gy Fx) Paclitaxel (50mg/m2/weekly X 6) Carboplatin (AUC 2/weekly X 6)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed, newly diagnosed, unilateral primary&#xD;
             non-small cell lung cancer (NSCLC)&#xD;
&#xD;
               -  Must have involvement of the superior sulcus, chest wall, or mediastinum&#xD;
&#xD;
          -  Must have at least 1 of the following:&#xD;
&#xD;
               -  Locally advanced Pancoast tumors with no documented mediastinal or&#xD;
                  supraclavicular nodal involvement (T3-T4, N0-1)&#xD;
&#xD;
               -  Resectable chest wall disease (T3, N0-1)&#xD;
&#xD;
               -  Marginally resectable T4, N0-1, or NX central NSCLC&#xD;
&#xD;
               -  N2 patients who are potentially resectable after induction chemoradiotherapy&#xD;
&#xD;
          -  No evidence of extrathoracic spread to liver, adrenals, brain, or bone&#xD;
&#xD;
          -  No evidence of supraclavicular nodes, malignant pleural or pericardial effusions, or&#xD;
             distant metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 2,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  SGOT no greater than 3 times upper limit of normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No superior vena cava syndrome&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No active uncontrolled congestive heart failure&#xD;
&#xD;
          -  No active uncontrolled arrhythmia within the past 6 months&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  FEV1 at least 800 mL&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other active invasive malignancy requiring therapy within the past 2 years&#xD;
&#xD;
          -  No ongoing need for adjuvant therapy&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for at least 3 months&#xD;
             after study entry&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior pelvic or thoracic radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Concurrent beta blockers, digitalis derivatives, or channel-blocking agents allowed&#xD;
             provided cardiac conditions are stable&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aruna J. Turaka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fox Chase Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fox Chase Cancer Center - Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111-2497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 5, 2002</study_first_submitted>
  <study_first_submitted_qc>May 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2003</study_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II non-small cell lung cancer</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 4, 2004</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT00043108/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

